The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

Since then AZ and Teva have bought rivals to market, but if approved in CRSwNP Nucala will take on Sanofi’s Dupixent (dupilumab) which has a different mechanism of action and was FDA-approved in ...

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...

For the CRSwNP indication, the BLA includes data from the ANCHOR-1 (ClinicalTrials.gov Identifier: NCT05274750) and ANCHOR-2 (ClinicalTrials.gov Identifier: NCT05281523) trials, which enrolled ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the use of Nucala, a monoclonal antibody that targets ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

The prescribed dosage for Nucala (mepolizumab) may vary depending on a person’s individual treatment plan, specific diagnosis, and age. Typically, Nucala is given once every 4 weeks as a ...

Nucala (mepolizumab) is a prescription drug used to treat a certain kind of asthma and some other immune-related conditions. The drug is typically given once every 4 weeks as an injection under ...

(Alliance News) - GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China ...

Submission based on data from MATINEE trial, which showed a significant and clinically meaningful reduction in rate of moderate/severe exacerbations with Nucala compared to placebo · Data ...